BPC-157
ProtocolFor protocol designers building BPC-157 into a multi-compound regimen, the practical questions are pharmacokinetic compatibility, route compatibility, receptor non-overlap, and operational scheduling around real-world constraints (travel, meals, training). The 250-500 mcg 1-2x daily dose at ~4 hr (oral) half-life informs which scheduling pattern fits.
Key Takeaways
Scheduling lens: BPC-157's ~4 hr (oral) half-life via subq/oral places it in the daily-dosing bucket. Mechanism: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Cycle structure: 8-12 weeks on, 4 weeks off; the off-period is functionally required for receptor reset. Stack scheduling: add one compound at a time with 2 weeks of isolated dosing before layering. Schedule-compatible stack partners: TB-500, Ipamorelin, CJC-1295 without DAC (Mod GRF 1-29).
Protocol calendar planning for BPC-157 is shaped by mechanism, pharmacokinetics, and operational reality. Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Modulates the gut-brain axis via vagal afferents to influence central serotonin and dopamine signalling. Reduces neuroinflammatory cytokines. The subsections below work through the daily timing patterns, the 8-12 week cycle structure with calibrated off-period, the stack scheduling principles, and the travel-and-disruption playbook.
Stack scheduling with other compounds
When BPC-157 is part of a multi-compound stack, the scheduling question becomes how to time its dose relative to the others. Oral and subcutaneous compounds can be timed independently; the routes do not interact. The pragmatic schedule reflects both pharmacokinetic constraints and the user's operational reality.
Travel, schedule shifts, and continuity
Maintaining cycle continuity through travel, time-zone shifts, and irregular schedules is one of the practical considerations for any BPC-157 protocol. Cold-chain requirements (where applicable), customs considerations for international travel, and adjustment for time-zone shifts within a 24–48 hour window are the main operational issues. For most BPC-157 schedules a ±8-hour timing shift has no clinical effect; longer shifts warrant minor schedule adjustment.
Daily and weekly timing
BPC-157 with a ~4 hr (oral) half-life pharmacokinetic profile sits in the daily-dosing bucket. The schedule is best built around either 1-2x daily, with consistency mattering more than the absolute clock time of any single dose.
Schedule design for BPC-157 in multi-peptide timing starts from pharmacokinetic constraints: less frequent dosing for long half-life compounds. The cycle length and off-period are then layered on top of the daily schedule.
The most-asked scheduling question for BPC-157 in protocol calendar is when to time doses relative to meals and training. The general principle: fasted dosing for compounds engaging the GH axis or AMPK; meal-paired dosing for incretins; flexibility for compounds whose pharmacokinetics permit it.
For loading phase scheduling, BPC-157 is best run in 8–12 week cycles with 4 week off-periods. Daily timing within the cycle is calibrated to pharmacokinetics; weekly timing is calibrated to training and lifestyle constraints. The schedule is the protocol.
Schedule design for BPC-157 in stack scheduling starts from pharmacokinetic constraints: less frequent dosing for long half-life compounds. The cycle length and off-period are then layered on top of the daily schedule.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | SubQ | 250-500 mcg | 8–12 weeks on / 4 weeks off |
| Conservative starter | SubQ | 150-500 mcg | 4–6 weeks initial cycle |
| Protocol focus | SubQ | 250-500 mcg | 1-2x daily |
| Maintenance phase | SubQ | 175-500 mcg | Ongoing with periodic pauses |
Dose timing for BPC-157 is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses.
BPC-157 stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from protocol designers.
- BPC-157 + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with BPC-157's mechanism in protocol / scheduling / cycling protocols.
- BPC-157 + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with BPC-157's mechanism in protocol / scheduling / cycling protocols.
- BPC-157 + CJC-1295 without DAC (Mod GRF 1-29): Same GHRH-receptor agonism as DAC variant. Pairs naturally with BPC-157's mechanism in protocol / scheduling / cycling protocols.
- BPC-157 + Semax: Elevates BDNF and NGF in hippocampus and cortex. Pairs naturally with BPC-157's mechanism in protocol / scheduling / cycling protocols.
Generally well tolerated in animal models. No large-scale human RCTs. Avoid in active cancer due to angiogenic activity.
Lens-specific safety considerations for protocol / scheduling / cycling use of BPC-157: Generally well tolerated in animal models. No large-scale human RCTs. Avoid in active cancer due to angiogenic activity. Additional protocol / scheduling / cycling monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| BPC-157 | Stable gastric pentadecapeptide | ~4 hr (oral) | Protocol |
| TB-500 | Synthetic thymosin β4 fragment | ~2-3 days | A 17-amino-acid synthetic fragment of thymosin β4 with actin-sequestering activity — drives cell migration, tissue repair, and broad regenerative effects |
| Ipamorelin | Selective GHRP / ghrelin mimetic | ~2 hr | The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite |
| GHK-Cu | Tripeptide-copper complex | ~30 min plasma | A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression |
Best practice for re-cycling?
What if I miss a dose?
When to integrate BPC-157 into an existing stack?
Stack timing relative to training and meals?
What is the mechanism of action of BPC-157?
What class of compound is BPC-157?
Start a BPC-157 Protocol
Alukard provides physician-supervised peptide protocols with GMP-certified BPC-157 and GMP-certified compounds with personalised cycle design.
Get ProtocolQuick Facts
- Molecular weight
- 1419.5 Da
- Sequence length
- 15 aa
- Half-life
- ~4 hr (oral)
- WADA
- Banned (2022→)
- FDA
- Unapproved (Research Only)
- Research
- Preclinical + Limited Human
Stack Partners
All protocol / scheduling / cycling applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for BPC-157 unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Protocol / Scheduling / Cycling Protocol for BPC-157
Alukard provides physician-supervised peptide protocols with GMP-certified compounds with personalised cycle design.
HIPAA Compliant · GMP Certified · Physician Supervised